Kornimate/medical-research-clean huggingface dataset:
the effect of magnesium sulfate on motor and somatosensory evoked potentials in children undergoing scoliosis surgery

Conditions: Scoliosis

Summary: the primary objective of this study is to determine whether magnesium sulfate has a clinically important effect on the amplitude and latency of somatosensory and motor evoked potentials in patients undergoing surgical correction of idiopathic scoliosis.

motor and somatosensory evoked potentials are continuously monitored in the setting of scoliosis surgery to evaluate the integrity of spinal cord pathways. detection of neural irritation or injury using motor or somatosensory evoked potentials allows the surgeon to modify technique to reverse the insult and proceed without spinal cord compromise. to facilitate evoked potential monitoring, anesthetic agents that attenuate the evoked responses must be avoided.several different agents have been studied to try to diminish the acute opioid tolerance and/or hyperalgesia seen with remifentanil. two studies investigated the effect of magnesium sulfate on intraoperative remifentanil-induced hyperalgesia. in both studies, post-operative pain scores and opioid consumption were decreased in those patients who received magnesium. our aim is to establish that magnesium sulfate does not adversely affect somatosensory evoked potentials (seps) and motor evoked potentials (meps) in patients undergoing correction of idiopathic scoliosis. future clinical trials can then be performed investigating the effect of magnesium sulfate on remifentanil-induced hyperalgesia in the same population.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) status i or ii * adolescent children aged 12 to 18 years undergoing surgery for idiopathic scoliosis exclusion criteria: * magnesium use within the last two weeks, either intravenous or oral supplements * patients with known electrolyte imbalances or conduction disorders. (sodium \ 143 mmol/l or potassium \ 5.0 mmol/l if 12 to 15 yrs; potassium \ 4.8 mmol/l if 16 to 18 yrs) * renal, cardiac or neuromuscular disorders.(urea \ 7.1 mmol/l or creatinine \>79 µmol/l if \ 98 µmol/l if \>= 14 yrs)

Keywords: pediatrics anaesthesia scoliosis magnesium
fecal metabolome and the intestinal microbiota in irritable bowel syndrome

Conditions: IBS

Summary: the purpose of this study is to find out the relationship between the bile acids, fatty acids (fatty acids are part of the diet) and bacteria that are present in the intestines.

there is emerging evidence that alterations in bile acids and scfa associated with ibs could be associated with changes in the gut microbiota. in addition to modulating levels of intraluminal organic acids, it has been hypothesized that gut microbiota may alter local immune responses, modulate visceral pain responses, and impair gut barrier function. our overall goal is to investigate the relationship between fecal bile acids, scfa and the gut microbiota in ibs. results of this pilot study could reveal insights into the interplay of the gut microbiota and small molecule mediators of ibs to suggest targeted clinical strategies for improved diagnosis and management of this important syndrome. aim 1: test the hypothesis that fecal organic acids (sfca and bile acids) and fecal microbiota play an important role in ibs. aim 2: test the hypothesis that there is association between colonic transit and fecal microbiota in ibs

Eligibility criteria:
inclusion criteria: * patients with ibs, ages 18-65 fulfilling rome iv criteria and asymptomatic controls with no prior history of gi disease or symptoms. * participants should be on a stable and consistent diet regimen and should not be following an extreme diet intervention such as gluten-free or a low fodmap diet at the time of study participation. exclusion criteria: * participants with microscopic/lymphocytic/collagenous colitis, inflammatory bowel disease, celiac disease, visceral cancer, chronic infectious disease, immunodeficiency, uncontrolled thyroid disease, history of liver disease or history of elevated ast/alt \> 2.0x the upper limit of normal * prior radiation therapy of the abdomen or abdominal surgeries with the exception of appendectomy or cholecystectomy \> 6 months prior to study initiation * ingestion of any prescription, over the counter, or herbal medications which can affect gi transit or study interpretation (e.g. opioids, narcotics, anticholinergics, norepinephrine reuptake inhibitors, nonsteroidal anti-inflammatory drugs, cox-2 inhibitors, bile acid sequestrants) within 6 months of study initiation for asymptomatic volunteers or within 2 days before study initiation for ibs patients * any females who are pregnant or trying to become pregnant or breast-feeding * antibiotic usage within 3 months prior to study participation * prebiotic or probiotic usage within the 2 weeks prior to study initiation * use of tobacco products within the past 6 months.
the prediction for postoperative pain

Conditions: Pain, Postoperative; Nociceptive Pain; Analgesia, Patient-Controlled; Analgesics

Summary: if the individual patient's pain is assessed and the amount of analgesic needed after surgery is predicted, appropriate injection of pain control and excessive injection of narcotic analgesic can be prevented. therefore, investigators try to evaluate the degree of pain during surgery and the amount of analgesic use for management of postoperative pain.

post-operative pain not only alleviates patient discomfort, but also delays recovery and thus prolongs the hospital stay. there are many ways to control postoperative pain, but analgesic infusion through venous route, patient controlled analgesia (pca), especially narcotic analgesics, is often used to control the infusion when needed. however, because pca is based on only age, weight, and underlying diseases, there are limitations in effective analgesia, and excessive sedation due to excessive infusion. therefore, if the individual patient's pain is assessed and the amount of analgesic needed after surgery is predicted, appropriate injection of pain control and excessive injection of narcotic analgesic can be prevented. the noxious stimuli during surgery may have a negative effect on the healing process and surgical outcome of the wound due to stress reaction and catabolism, secretion of pituitary hormone, activation of the sympathetic nervous system, and immunological changes. therefore, proper analgesia is needed during general anesthesia. a non-invasive, non-invasive analgesic device is currently available for surgical pleth index (spi) to assess the status of intraoperative analgesia. spi = 100- (0.3 \* heart beat interval + 0.7 \* photoplethysmographic pulse wave amplitude) is automatically and continuously calculated from the waveform of peripheral oxygen saturation. in the postoperative pain prediction study with spi, the spi value at the end of the operation was found to be proportional to the pain in the recovery room. however, only the pain score immediately after the operation was confirmed in these studies. therefore, investigators try to evaluate the degree of pain during surgery and the amount of analgesic use for management of postoperative pain.

Eligibility criteria:
inclusion criteria: undergoing liver resection (laparoscopic or laparotomy) exclusion criteria: patients who refused to participate patients who have cardiac arrythmia patients who have allergic history for remifentanil
a study to investigate the safety, toleration and efficacy of pf00610355 in chronic obstructive pulmonary disease (copd) patients.

Conditions: Pulmonary Disease, Chronic Obstructive; Lung Diseases; Lung Diseases, Obstructive

Summary: to assess the effects and safety of pf-00610355 on patients with chronic obstructive lung disease (copd)


Eligibility criteria:
inclusion criteria: * post-bronchodilator fev1/fvc ratio \<0.7 and a post-bronchodilator fev1 of 50-80%. * diagnosis of moderate copd for a minimum of 6 months. * stable disease for at least 1 month prior to screening exclusion criteria: * more than 2 exacerbations of copd requiring treatment with oral steroids in the preceding year or hospitalisation for the treatment of copd within 3 months of screening or more than twice during the preceding year. * history of a lower respiratory tract infection or significant disease instability during the month preceding screening or during the time between screening and randomisation.

Keywords: copd respiratory long acting beta agonist
continuous chest wall vibration in copd rehabilitation

Conditions: COPD

Summary: dyspnea, the sensation of breathing discomfort or shortness of breath, is one of the main symptoms for patients affected by chronic obstructive pulmonary disease (copd), particularly during exercise. previous study show that chest wall vibration decrease dyspnea in copd patients and precisely when applied during the inspiration phase, called "in-phase vibration" (ipv) which provide vibration directly on intercostal muscles. these findings have been obtained in laboratory context and the intercostals muscles vibration has been tested only in single phases of breathing, during inspiration with ipv and during exhalation with out-of-phase vibration (opv). none study has evaluated the effect of a continuous chest wall vibration (ccwv), namely muscles vibration during the whole cycle of breathing, on dyspnea in patients with copd in a clinical context. continuous high frequency vibration has been proven to reduce myoelectrical manifestation of fatigue, probably modifying the centrally driven motor unit recruitment hierarchy, in healthy subjects. moreover, ccwv is a modality of provide vibration more suitable and cost-effective in a clinical context than single-phases vibration that requires specific instruments for the detection of breathing phases and the coupling with vibration device. on these bases, the investigators hypothesized that ccwv at high frequency, applied during a cycle ergometer training program, could decrease dyspnea and enhance the exercise tolerance in copd patients. therefore, the aim of this study is to evaluate the effects of high frequency ccwv on dyspnea and exercise tolerance in patients with copd patients compared to usual care and to sham intervention.


Eligibility criteria:
inclusion criteria: - copd diagnosis (gold stage: 2-3-4) exclusion criteria: * restrictive lung disease * active pulmonary infection * pulmonary embolism (less than 3 months) * pneumotorax * thoracic/abdominal operation (less than 3 months) * myocardial infarction (less than 6 months) * congestive heart failure/ heart failure/ right heart failure * angina/severe angina * incapability of perform the cycle ergometer training (e.g. orthopaedic or urogenital conditions) * incapability to understand the intructions required to carry out the tests and assessments planned

Keywords: copd vibration rehabilitation
short term comparative study of xalatan with benzalkonium chloride vs. travatan z without benzalkonium chloride in healthy volunteers

Conditions: Glaucoma

Summary: compare the effect of xalatan with benzalkonium chloride on the ocular surface to those effects observed with travatan z without benzalkonium chloride after a single dose


Eligibility criteria:
inclusion criteria: * adults with primary open-angle glaucoma, ocular hypertension or pigment dispersion glaucoma exclusion criteria: * age
eus-fna for retropharyngeal lymph node (rpln) in recurrent nasopharyngeal carcinoma (npc) patients

Conditions: Nasopharyngeal Carcinoma

Summary: eus-fna for rpln in npc

to evaluate the safety and efficacy of a novel minimally invasive sampling technique -- fine needle aspiration (fna) guided by endoscopic ultrasound (eus), which aims to sample tissues from retropharyngeal lymph nodes (rpln) for the diagnosis of patients with suspected recurrent nasopharyngeal carcinoma (npc).

Eligibility criteria:
inclusion criteria: 1. had undifferentiated, non-keratinizing carcinoma at the initial diagnosis (who, 1991 criteria) and no evidence of distant metastasis obtained before radiotherapy; 2. received regular chemotherapy with cytotoxic agents such as cisplatin, carboplatin, 5-fluorouracil, paclitaxel, etc, and coordinated with radiotherapy with standard doses (approximate 50-70 gy) in nasopharynx and neck respectively. within 3 months after radiotherapy, no local and distant lesions were found; 3. during regular follow-up , the enlarged rpln was detected by mri more than 6 months later since radiotherapy accomplished; 4. didn't receive chemotherapy radiotherapy, immunotherapy or salvage surgery from completion of radiotherapy to suspicious recurrent lesion in rpln detected; 5. no recurrent lesion in nasopharynx was found by white light endoscopy as well as cancer cell negative in pathology by bite biopsy; 6. single lesion in rpln, and no other recurrent or metastatic lesion was found in local region or distant organ. 7. the minimum axial diameter of rpln was more than 5mm. exclusion criteria: * (1) patients with nasal stenosis; (2) patients with coagulation dysfunction; (3) patients with distant metastasis

Keywords: fna,eus,retropharyngeal lymph node (rpln),npc
the intestinal function in people with prader-willi syndrome

Conditions: Prader-Willi Syndrome; Constipation; Incontinence

Summary: the projects aim is to investigate the intestinal function of patients suffering from prader-willi syndrome. the methods used are ultrasonographic measurement of the rectal diameter and gastrointestinal transit time

prader-willi syndrome (pws) is a congenital genetical disease characterized by moderate retardation, food-seeking behavior and a serious risk of developing health threatening overweight, low stature, abnormal body composition and a lack of growth- and sex-hormones. they can not live an independent life and are reliant of help from care personnel. people with pws react abnormally to signals from their own bodies. e.g. they have a reduced sense of pain and can have a lacking urge to urination despite a full bladder. most of the patients also have a relatively slow pulse, which can be consistent with a dysfunction in the nervous system (the parasympathetic nervous system) which also has large significance for the bladder- and bowel function. the intestinal function in people with pws is a sparse described subject, which has not been systematically examined in scientific context. we therefore want to examine whether the bowel function in people with pws are different from the bowel function in healthy people. the subject is elucidated by a medical examination, a questionnaire, a registration of toilet habits, a measurement of the rectal diameter by an ultrasound scan and a measurement of the colonic transit time. the results will be compared to findings in normal healthy people. because no normal material exists for rectal diameter measured by ultrasound, we will establish one. the result of the project will increase our knowledge of possible bowel dysfunctions such as constipation, in people with pws and can immediately lead to improved care for and optimized treatment of the patients.

Eligibility criteria:
inclusion criteria: * age above 18 * \>14 days since last antibiotic treatment * \>14 days since last laxative treatment * pws confirmed genetically exclusion criteria: * previous abdominal surgery (except appendectomy or haemorrhoidectomy * patient not capable of understanding the information * treatment with eltroxin or antipsychotic medication * pregnancy
ultrasound guided diagnostic cervical medial branch block

Conditions: Facet Joint Pain; Neck Pain

Summary: the diagnostic cervical branch block for neck pain due to cervical facet joint pain has been traditionally done under fluoroscopic guidance. its diagnostic value and technique have been well established. however, recently some studies have shown that the diagnostic cervical and lumbar medial branch block can be done under ultrasound guidance.


Eligibility criteria:
inclusion criteria: * healthy volunteers * patients who have headache, neck pain, and shoulder pain due to possible facet joint disease exclusion criteria: * patients/volunteers with bmi \> 35 * patients/volunteers with short thick neck * coagulopathy * allergy to local anesthetic, ultrasound gel * patient unable to fill out post procedure pain diary

Keywords: cervical branch block fluoroscopic guidance ultrasound guidance
visual and optics impact of refractive surgery

Conditions: Refractive Disorders

Summary: refractive surgery includes interventions to correct refractive errors, using a medical device such as a laser or an implant (intraocular lenses) or surgical instruments. the study distinguishes corneal interventions, carried on the surface of the eye, and intraocular interventions, performed on the lens or in the anterior or posterior chamber of the eye. the number of procedures in refractive surgery is growing significantly. they seem to offer satisfactory visual results but a number of issues remains unresolved. in order to get emmetropia, refractive surgery corrects optical defects by decreasing aberrations of lower orders (ie spherical refractive error and astigmatism). this increases high-order aberrations (the most common is a bright halo on the edge of the image). the cutting of the flap to the surface of the cornea in the case of lasik increases high-order aberrations, which have the effect of reducing post-surgical visual performance (ie visual acuity and contrast sensitivity) and can't be corrected by glasses, while the adaptation of contact lenses on a post-operative cornea is more complex. it is therefore necessary to limit these post-surgical aberrations and to identify their possible sources. indeed, some authors have provided insight into the effects of some high-order aberrations, but the influence of several factors characterizing the preoperative eye on refractive surgery are still unknown, such as pupillary diameter, depth of the anterior chamber, intra ocular pressure or astigmatism.


Eligibility criteria:
inclusion criteria: * patient candidate for laser in situ keratomileusis (lasik) refractive surgery * 18 to 40 years old * corrective glasses or lenses ranging from -9.00 to + 6.00 diopter * astigmatism less than or equal to 5 diopter exclusion criteria: * patient opposition to participate in the study * patient under legal protection * pregnant or breast feeding patient * no health insurance coverage

Keywords: refractive surgery higher order aberrations
comparison of pantomiming and easy onset treatment

Conditions: Stammering

Summary: this research will give in-depth understanding of pantomiming and easy onset method as an intervention of stuttering and especially blocking. and by comparing both methods, it will also determine that which method is more effective. this research will also improve the overall awareness regarding stuttering

research participants will be divided into two groups through randomization, group a \& group b. base line assessment will be conducted. intervention will be provided (thrice a week on alternative days).post assessment will be taken and data will be analyzed through spss.

Eligibility criteria:
inclusion criteria: * participants falling in this category would be added into the study. * school aged children and adolescents ages between 6 to 18 years(both genders) who stutter with blocking symptoms * participant who will be at moderate level of stammering will be included exclusion criteria: * participant failing to fall in this category would be excluded of the study. * participants with any other medical condition will be excluded

Keywords: pantomiming easy onset method blocking
retrospective evaluation of 3 colonic adenoma detection strategies

Conditions: Adenoma Colon; Colorectal Cancer; Colorectal Polyp; Colonic Adenocarcinoma

Summary: retrospective study, single blind (patient), allowing a posteriori clinical data collection of 90 patients during their passage to the ambulatory endoscopy circuit, to consider 3 groups and thus to deduce a colonic adenoma detection rate for each arm : * colonoscopy only group * artificial intelligence only group (ia gi genius ™ alone) * endoscopic cap and artificial intelligence group (endoscopy cap associated with the gi genius ™ ia system)


Eligibility criteria:
inclusion criteria : * 18 years \< patient \< 85 years * need to perform a primary and / or secondary screening colonoscopy for colorectal cancer * patients candidates for outpatient care exclusion criteria : * history of inflammatory digestive tract disease * failed previous colonoscopy * known familial polyposis * biopsy / polypectomy contraindication (coagulation disorder, treatment with clopidogrel / anticoagulant)
empire cf: a phase 2 study to evaluate the efficacy, safety, and tolerability of ctx-4430 in adult cystic fibrosis (cf) patients

Conditions: Cystic Fibrosis

Summary: this study is a phase 2, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of ctx-4430 administered once-daily for 48 weeks for treatment of cf.

this study is a phase 2, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of ctx-4430 administered once-daily for 48 weeks for treatment of cf. a total of 195 pulmonary cf patients that meet all the inclusion and no exclusion criteria and provide written informed consent will be randomized to receive 50 mg ctx-4430, 100 mg ctx-4430, or placebo in a 1:1:1 ratio. follow-up visits will be conducted approximately every 4 weeks from week 4 to week 52 (4 weeks after completion of treatment).

Eligibility criteria:
inclusion criteria: * forced expiratory volume at one second (fev1) ≥50 percent predicted at screening * at least 1 pulmonary exacerbation in the 12 months before screening exclusion criteria: * pregnant or nursing women * medical condition that is unstable, could be adversely impacted by participation in the study, or could impact assessment of the study results * history of organ transplantation * history of alcoholism or drug abuse within 2 years before screening * regular use of a high-dose nsaid within 60 days before screening
study of the effect of diquafosol tetrasodium ophthalmic solution, 2% versus placebo in dry eye subjects (p08634)

Conditions: Dry Eye Disease

Summary: the purpose of this pilot study is to evaluate the effect of diquafosol tetrasodium ophthalmic solution, 2% in dry eye subjects.


Eligibility criteria:
inclusion criteria: * provide written informed consent prior to any study procedures being performed. * have a best corrected visual acuity (bcvaof +0.7 or better. * have a history of dry eye (keratoconjunctivitis sicca) in both eyes * have ongoing dry eye disease, in the same qualifying eye or both eyes. exclusion criteria: * have previously had lasik refractive surgery. * use of topical ophthalmic medications, preps, gels and lid scrubs during study. * have had penetrating intraocular surgery in the past 90 days. * have had other ocular surface surgery (e.g., refractive, pterygium) within the past year. * have a diagnosis of an on-going ocular infection, clinically significant blepharitis, lid margin inflammation, stevens-johnson syndrome or pemphigoid. * any serious ocular systemic disease or uncontrolled medical condition. * exposure to any investigational drug within 30 days of study start.